C-type natriuretic peptide (CNP) is expressed from numerous tissue types but primarily within the central nervous system and the bone. CNP binds the natriuretic peptide receptor B (NPR-B) and acts as an autocrine/paracrine factor. CNP signalling acts as a positive regulator of endochondral bone growth. Both CNP and NPR-B are being explored as therapeutic targets for growth disorders including achondroplasia. CNP (1-22) is the major form of CNP found in the plasma. Exogenous CNP (1-22) can be cleared quite effectively, administration of a constant “high” dose was able to overcome this obstacle to induce endochondral ossification and accelerated bone growth. However, CNP (1-22) may have the potential to induce systemic vascular resistance and blood pressure issues which would need to be addressed before future clinical applications. Researchers are trying to better establish the function and role of CNP (1-22); one strategy has been the addition of conjugates, such as the C-terminal of ghrelin, to try and improve the clinical efficacy.